During omicron, risk for SARS-CoV-2 infection dependent on antibody response to COVID-19 vaccine regardless of number of doses
Vaccination Cuts Risk of Severe COVID-19 in Patients on Dialysis
Reduction in risk of admission and deaths with prior two-dose vaccination versus no vaccination
Vaccine Rollout Linked to Drop in Severe COVID-19 in Dialysis Patients
And, patients on maintenance dialysis who received COVID-19 vaccination had decreasing antibody titers over time
Humoral Response in Hemodialysis Patients Stronger With mRNA-1273
Antibody responses at six to seven and 12 weeks after the second dose stronger with mRNA-1273 versus BNT162b2
Antibody Response to SARS-CoV-2 Wanes Among Dialysis Patients
Prebreakthrough index RBD values of <10 and 10 to <23 associated with increased odds of breakthrough infection versus value of ≥23
For Dialysis Recipients, Antibody Response Lowest With Ad26.COV2.S
Patients receiving attenuated adenovirus vaccine more likely to have no seroconversion, no detectable or diminished IgG response
Hemodialysis Patients Have Antibody Response to COVID-19 Vaccine
But few kidney transplant recipients develop anti-spike SARS-CoV-2 antibodies after second mRNA vaccine dose
Factors ID’d for COVID-19 Infection Risk in Dialysis Patients
Age, diabetes, local community COVID-19 rates, dialysis unit size linked to positive test for infection or admission with suspected COVID-19
One Dose of BNT162b2 Inadequate for Hemodialysis Patients
Single mRNA vaccine dose often fails to elicit a humoral response; 57 percent of dialysis patients have undetectable anti-RBD IgG at four weeks
Dialysis Patients Maintain Humoral Response to SARS-CoV-2 Infection
SARS-CoV-2 receptor-binding domain IgG persisted over six months followed by slow, continual decline
- Page 1 of 2
- 1
- 2